Clinical pharmacology and efficacy of vancomycin in pediatric patients

Paul S. Lietman, Urs B. Schaad, George H. McCracken, John D. Nelson

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

The emergence of staphylococci resistant to multiple antibiotics and the lack of information on pharmacology, efficacy, and safety of vancomycin in pediatric patients prompted this study. In vitro susceptibility studies showed that 33 to 50% of staphylococci tested were resistant to nafcillin, methicillin, cephalothin, and gentamicin, whereas none were resistant to vancomycin. Pharmacokinetic data of vancomycin were evaluated in 55 pediatric patients and was characterized by the two-compartment open-system kinetic model. Mean peak serum concentrations in infants and children after 10 and 15 mg/kg doses ranged from 25.2 to 32.5 μg/ml. The 10 mg/kg dose in newborn infants resulted in substantially lower peak values. Mean serum elimination phase half-life values correlated inversely with gestational and chronologic age and ranged from 2.2 to 9.8 hours. The CSF penetration in three infants with staphylococcal ventriculoperitoneal shunt infections ranged from 7 to 21%. Sixteen patients with staphylococcal diseases were successfully treated with vancomycin. In these patients peak serum vancomycin concentrations greater than 25 μg/ml and trough concentrations less than 12 μg/ml produced satisfactory inhibitory and bactericidal titers. Laboratory studies and auditory function tests did not reveal any drug-related abnormalities. Dosage schedules were formulated from these data. Indications and precautions for vancomycin therapy in infants and children are presented.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalThe Journal of Pediatrics
Volume96
Issue number1
DOIs
StatePublished - 1980

Fingerprint

Clinical Pharmacology
Vancomycin
Pediatrics
Staphylococcus
Nafcillin
Serum
Cephalothin
Ventriculoperitoneal Shunt
Methicillin
Gentamicins
Gestational Age
Half-Life
Appointments and Schedules
Pharmacokinetics
Newborn Infant
Pharmacology
Anti-Bacterial Agents
Safety
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Clinical pharmacology and efficacy of vancomycin in pediatric patients. / Lietman, Paul S.; Schaad, Urs B.; McCracken, George H.; Nelson, John D.

In: The Journal of Pediatrics, Vol. 96, No. 1, 1980, p. 119-126.

Research output: Contribution to journalArticle

@article{e5d9fff4784748cfae275800df282a2c,
title = "Clinical pharmacology and efficacy of vancomycin in pediatric patients",
abstract = "The emergence of staphylococci resistant to multiple antibiotics and the lack of information on pharmacology, efficacy, and safety of vancomycin in pediatric patients prompted this study. In vitro susceptibility studies showed that 33 to 50{\%} of staphylococci tested were resistant to nafcillin, methicillin, cephalothin, and gentamicin, whereas none were resistant to vancomycin. Pharmacokinetic data of vancomycin were evaluated in 55 pediatric patients and was characterized by the two-compartment open-system kinetic model. Mean peak serum concentrations in infants and children after 10 and 15 mg/kg doses ranged from 25.2 to 32.5 μg/ml. The 10 mg/kg dose in newborn infants resulted in substantially lower peak values. Mean serum elimination phase half-life values correlated inversely with gestational and chronologic age and ranged from 2.2 to 9.8 hours. The CSF penetration in three infants with staphylococcal ventriculoperitoneal shunt infections ranged from 7 to 21{\%}. Sixteen patients with staphylococcal diseases were successfully treated with vancomycin. In these patients peak serum vancomycin concentrations greater than 25 μg/ml and trough concentrations less than 12 μg/ml produced satisfactory inhibitory and bactericidal titers. Laboratory studies and auditory function tests did not reveal any drug-related abnormalities. Dosage schedules were formulated from these data. Indications and precautions for vancomycin therapy in infants and children are presented.",
author = "Lietman, {Paul S.} and Schaad, {Urs B.} and McCracken, {George H.} and Nelson, {John D.}",
year = "1980",
doi = "10.1016/S0022-3476(80)80347-7",
language = "English (US)",
volume = "96",
pages = "119--126",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical pharmacology and efficacy of vancomycin in pediatric patients

AU - Lietman, Paul S.

AU - Schaad, Urs B.

AU - McCracken, George H.

AU - Nelson, John D.

PY - 1980

Y1 - 1980

N2 - The emergence of staphylococci resistant to multiple antibiotics and the lack of information on pharmacology, efficacy, and safety of vancomycin in pediatric patients prompted this study. In vitro susceptibility studies showed that 33 to 50% of staphylococci tested were resistant to nafcillin, methicillin, cephalothin, and gentamicin, whereas none were resistant to vancomycin. Pharmacokinetic data of vancomycin were evaluated in 55 pediatric patients and was characterized by the two-compartment open-system kinetic model. Mean peak serum concentrations in infants and children after 10 and 15 mg/kg doses ranged from 25.2 to 32.5 μg/ml. The 10 mg/kg dose in newborn infants resulted in substantially lower peak values. Mean serum elimination phase half-life values correlated inversely with gestational and chronologic age and ranged from 2.2 to 9.8 hours. The CSF penetration in three infants with staphylococcal ventriculoperitoneal shunt infections ranged from 7 to 21%. Sixteen patients with staphylococcal diseases were successfully treated with vancomycin. In these patients peak serum vancomycin concentrations greater than 25 μg/ml and trough concentrations less than 12 μg/ml produced satisfactory inhibitory and bactericidal titers. Laboratory studies and auditory function tests did not reveal any drug-related abnormalities. Dosage schedules were formulated from these data. Indications and precautions for vancomycin therapy in infants and children are presented.

AB - The emergence of staphylococci resistant to multiple antibiotics and the lack of information on pharmacology, efficacy, and safety of vancomycin in pediatric patients prompted this study. In vitro susceptibility studies showed that 33 to 50% of staphylococci tested were resistant to nafcillin, methicillin, cephalothin, and gentamicin, whereas none were resistant to vancomycin. Pharmacokinetic data of vancomycin were evaluated in 55 pediatric patients and was characterized by the two-compartment open-system kinetic model. Mean peak serum concentrations in infants and children after 10 and 15 mg/kg doses ranged from 25.2 to 32.5 μg/ml. The 10 mg/kg dose in newborn infants resulted in substantially lower peak values. Mean serum elimination phase half-life values correlated inversely with gestational and chronologic age and ranged from 2.2 to 9.8 hours. The CSF penetration in three infants with staphylococcal ventriculoperitoneal shunt infections ranged from 7 to 21%. Sixteen patients with staphylococcal diseases were successfully treated with vancomycin. In these patients peak serum vancomycin concentrations greater than 25 μg/ml and trough concentrations less than 12 μg/ml produced satisfactory inhibitory and bactericidal titers. Laboratory studies and auditory function tests did not reveal any drug-related abnormalities. Dosage schedules were formulated from these data. Indications and precautions for vancomycin therapy in infants and children are presented.

UR - http://www.scopus.com/inward/record.url?scp=0018877552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018877552&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(80)80347-7

DO - 10.1016/S0022-3476(80)80347-7

M3 - Article

C2 - 7350291

AN - SCOPUS:0018877552

VL - 96

SP - 119

EP - 126

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -